Results 61 to 70 of about 381,122 (317)

Diagnostic Performance of Bronchoalveolar Lavage (1,3)-β-d-Glucan Assay for Pneumocystis jirovecii Pneumonia

open access: yesJournal of Fungi, 2020
We evaluated the performance of the (1,3)-β-d-glucan (BDG) assay on bronchoalveolar lavage fluid (BALF) as a possible aid to the diagnosis of Pneumocystis jirovecii pneumonia.
Shiwei Zhou   +5 more
doaj   +1 more source

Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients [PDF]

open access: yes, 2003
Forty-seven bronchoalveolar lavage fluid samples from 16 human immunodeficiency virus (HIV)-infected patients were used to test the latency model of Pneumocystis infection in the human host.
Ambrose, HE   +4 more
core  

Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches.

open access: yesMedical Mycology, 2020
Pneumocystis jirovecii can cause life-threatening pneumonia in immunocompromised patients. Traditional diagnostic testing has relied on staining and direct visualization of the life-forms in bronchoalveolar lavage fluid.
M. Bateman, R. Oladele, J. Kolls
semanticscholar   +1 more source

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

open access: yesArthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian   +111 more
wiley   +1 more source

Ventilator-associated Pneumonia After Elective Cardiac Surgery Caused by Pneumocystis Jirovecii [PDF]

open access: yes, 2014
Ventilator-associated pneumonia is a severe complication among patients undergoing cardiac surgery. Although hospital-acquired bacterial pathogens, often multidrug resistant, are the most frequent cause, non-bacterial atypical and opportunistic agents ...
Cifuentes, M   +5 more
core  

The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: Case reports and literature review [PDF]

open access: yes, 2004
Background: Pneumocystis jiroveci pneumonia (PCP) is an important opportunistic infection among immunosuppressed patients, especially in those infected with human immunodeficiency virus (HIV). The clinical presentation of PCP in immunosuppressed patients
A Sing   +46 more
core   +2 more sources

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

open access: yesArthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman   +2 more
wiley   +1 more source

Nonhuman Primate Models of Respiratory Disease: Past, Present, and Future. [PDF]

open access: yes, 2017
The respiratory system consists of an integrated network of organs and structures that primarily function for gas exchange. In mammals, oxygen and carbon dioxide are transmitted through a complex respiratory tract, consisting of the nasal passages ...
Miller, Lisa   +3 more
core   +1 more source

Pharmacokinetics of dolutegravir, tenofovir and lamivudine during venous–venous extracorporeal membrane oxygenation (VV‐ECMO): A case report

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
While providing potentially life‐saving cardiorespiratory support for critically ill patients, extracorporeal membrane oxygenation (ECMO) may detrimentally affect pharmacokinetic (PK) performance and concurrent drug efficacy and safety. We describe a patient with Pneumocystis jirovecii pneumonia (PJP) in the context of acquired immunodeficiency ...
Tom C. Zwart   +7 more
wiley   +1 more source

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study

open access: yesInternational Journal of Cancer, EarlyView.
What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy